Zonisamide Capsules, which are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy, have total annualized sales of 170.30 million dollars, Ranbaxy informed the Stock Exchanges.
'Such partnerships with companies like Invagen, who have capabilities and competencies to develop bioequivalent generic product for the marketplace, are naturally beneficial to both organizations while having a positive economic impact on the US healthcare system,' Ranbaxy Inc President Atul Malhotra said.
(Source:PTI News)
